Overview
Metastatic neuroblastoma involving the central nervous system (CNS), particularly leptomeningeal dissemination, represents a highly challenging and often fatal complication in pediatric oncology. This condition primarily affects children with advanced-stage neuroblastoma, leading to significant morbidity and poor survival outcomes. Leptomeningeal metastases are characterized by the spread of tumor cells along the surfaces of the brain and spinal cord, often manifesting through neurological symptoms that reflect the disease's impact on the meninges and cerebrospinal fluid (CSF). The clinical management of these patients requires a multidisciplinary approach, integrating neuro-oncology, neurology, and palliative care to address both the aggressive nature of the disease and the complex ethical considerations that may arise, especially concerning end-of-life care and definitions of brain death.
Pathophysiology
Leptomeningeal dissemination in pediatric CNS tumors, including metastatic neuroblastoma, involves the infiltration of tumor cells into the subarachnoid and subdural spaces, leading to a diffuse and often multifocal involvement of the CNS. This process is distinct from focal parenchymal brain tumors such as medulloblastomas, ependymomas, and malignant gliomas, yet shares a grave prognosis characterized by rapid neurological decline. The pathophysiology underscores the critical role of the meninges and CSF in facilitating tumor spread, which can occur via hematogenous dissemination or direct extension from primary or regional metastatic sites [PMID:36949251]. The diffuse nature of leptomeningeal metastases complicates treatment, as it often evades localized therapies and necessitates systemic or targeted approaches to effectively reach the disseminated tumor cells. Understanding these mechanisms is crucial for developing strategies to interrupt the metastatic cascade and mitigate disease progression.
Clinical Presentation
The clinical presentation of metastatic neuroblastoma involving the CNS is marked by a constellation of neurological symptoms that reflect the extensive involvement of the meninges and CSF pathways. Patients commonly experience severe headaches, often described as persistent and worsening, which can be indicative of increased intracranial pressure. Cranial nerve dysfunction is another hallmark, manifesting as diplopia (third nerve involvement), facial weakness (seventh nerve involvement), or hearing loss (eighth nerve involvement), depending on the specific nerves affected. Additionally, patients may exhibit signs of diffuse neurological impairment, including confusion, altered mental status, motor deficits, and sensory disturbances. These symptoms can rapidly progress, underscoring the urgency in diagnosing and managing these cases [PMID:36949251]. Families often face profound emotional and ethical challenges, particularly as the disease progresses, leading to discussions around end-of-life care and the potential diagnosis of brain death by neurologic criteria (DNC). These discussions are further complicated by varying cultural and religious beliefs, which can influence treatment decisions and family expectations [PMID:33984463].
Diagnosis
Diagnosing leptomeningeal metastasis in neuroblastoma requires a comprehensive approach integrating clinical assessment with advanced imaging and cerebrospinal fluid (CSF) analysis. Magnetic resonance imaging (MRI) of the brain and spine, often supplemented with gadolinium contrast, is crucial for identifying characteristic leptomeningeal enhancement patterns indicative of tumor spread. Lumbar puncture for CSF analysis is essential, where cytology can reveal malignant cells, and molecular studies such as polymerase chain reaction (PCR) for specific neuroblastoma markers (e.g., N-MYC amplification) can confirm the diagnosis. Additionally, contrast-enhanced MRI and sometimes positron emission tomography (PET) scans may provide further insights into the extent of disease dissemination. Early and accurate diagnosis is pivotal for timely intervention, although the diffuse nature of leptomeningeal metastases can sometimes complicate definitive identification [PMID:36949251]. Ethical considerations, particularly around invasive diagnostic procedures in critically ill patients, necessitate careful consideration and family involvement to align with patient values and wishes [PMID:33984463].
Management
The management of metastatic neuroblastoma involving the CNS, particularly leptomeningeal dissemination, is multifaceted and challenging, aiming to alleviate symptoms, prolong survival, and improve quality of life. Intra-CSF chemotherapy represents a targeted approach to bypass the blood-brain barrier, delivering high concentrations of chemotherapeutic agents directly to the CNS. Etoposide, administered intraventricularly, is a cornerstone in this strategy, offering a localized effect with potentially fewer systemic toxicities compared to traditional systemic chemotherapy [PMID:36949251]. However, the efficacy of such treatments is often limited by the diffuse nature of the disease and the potential for rapid tumor progression.
Radiation therapy may also be considered, particularly for focal symptomatic lesions, to reduce intracranial pressure and alleviate neurological symptoms. However, its role is more limited in diffuse leptomeningeal disease due to the risk of neurotoxicity in pediatric patients. Supportive care is integral, encompassing management of symptoms such as pain, seizures, and hydrocephalus, often requiring neurosurgical interventions like ventriculoperitoneal (VP) shunt placement to manage increased intracranial pressure.
Pediatric palliative care plays a vital role throughout the course of the disease, providing holistic support to both the patient and the family. Palliative care teams address symptom management, emotional support, and facilitate discussions around end-of-life care, especially when facing the grim prognosis associated with leptomeningeal metastasis. These multidisciplinary efforts aim to optimize quality of life despite the often short survival times, typically ranging from a few weeks to a few months [PMID:36949251]. Ethical considerations, particularly around the definition of brain death and the right to refuse diagnostic procedures, necessitate sensitive and informed discussions with families, ensuring that care aligns with the patient's and family's values and wishes [PMID:33984463].
Complications
The management of metastatic neuroblastoma with leptomeningeal involvement is fraught with significant complications that can severely impact patient outcomes and quality of life. Infections, particularly those caused by Staphylococcus species, are a major concern following intra-CSF procedures. These infections can range from localized meningitis to more systemic sepsis, necessitating prompt antibiotic therapy and sometimes surgical intervention to remove infected devices such as Ommaya reservoirs [PMID:36949251]. Non-infectious complications include technical issues like device malposition, which can lead to inadequate drug delivery or complications such as CSF leaks and intracerebral hemorrhage. CSF leaks can result in post-dural puncture headaches, while intracerebral hemorrhages pose immediate risks to neurological function and survival. These complications underscore the need for meticulous monitoring and timely intervention to mitigate their impact on patient care and prognosis.
Prognosis & Follow-up
The prognosis for patients diagnosed with leptomeningeal metastasis from neuroblastoma remains grim, with survival times often measured in weeks to a few months, highlighting the aggressive nature of this disease [PMID:36949251]. Despite advances in targeted therapies and supportive care, the diffuse and often rapid progression of leptomeningeal metastases poses significant therapeutic challenges. Limited long-term follow-up data in pediatric populations further complicates the understanding of long-term outcomes and the effectiveness of various treatment modalities. Ethical and legal controversies surrounding brain death by neurologic criteria (DNC) significantly influence prognosis discussions and follow-up care, particularly as families navigate end-of-life decisions and potential legal challenges related to treatment withdrawal and palliative care preferences [PMID:33984463]. Comprehensive follow-up care should therefore integrate not only clinical monitoring but also psychological and ethical support to address the multifaceted needs of both patients and their families during this critical period.
References
1 Butler A, Meijer L, Liu JF, Chohan M, Jalloh I, Macarthur D et al.. Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2023. link 2 Sawyer KE, Kraft SA, Wightman AG, Clark JD. Pediatric Death by Neurologic Criteria: The Ever-Changing Landscape and the Expanding Role of Palliative Care Professionals. Journal of pain and symptom management 2021. link
2 papers cited of 4 indexed.